Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elranatamab for Inhibitor Eradication in Hemophilia A With Inhibitors
NCT07788469Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Oct 2026
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
Open-label, single-arm trial of elranatamab in hemophilia A, sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 1 year. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
elranatamab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT07788469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07788469.